Kishore Lakshman, MD
Endocrinology, Diabetes & Metabolism · Fall River, MANPI 1992909568
Payments from drug & device makers
Across 153 payments — averaging $60.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Antares Pharma, Inc.$5K
- Verity Pharmaceuticals Inc.$1K
- Novo Nordisk$669
- Abbott$518
- AbbVie$293
- Corcept Therapeutics$222
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$6,00065%
- Food & beverage$3,15134%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Antares Pharma, Inc. | 15 | $5,269 |
| Verity Pharmaceuticals Inc. | 4 | $1,090 |
| Novo Nordisk | 34 | $669 |
| Abbott | 22 | $518 |
| AbbVie | 15 | $293 |
| Corcept Therapeutics | 7 | $222 |
| AstraZeneca | 7 | $124 |
| Lilly USA, LLC | 5 | $123 |
| Novartis | 7 | $111 |
| Dexcom, Inc. | 5 | $105 |
| Amgen(2 entities) | 5 | $94 |
| Tolmar, Inc. | 2 | $62 |
| Medtronic | 3 | $59 |
| Cequr Corporation | 1 | $54 |
| Boehringer Ingelheim | 2 | $45 |
| Halozyme Inc | 2 | $41 |
| Shire North American Group Inc | 2 | $37 |
| Bayer | 2 | $32 |
| Nevro Corp. | 1 | $32 |
| Tandem Diabetes Care, Inc. | 1 | $27 |
| Insulet Corporation | 1 | $26 |
| Zealand Pharma US, Inc. | 1 | $26 |
| RGH Enterprises LLC | 1 | $25 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| Lifescan, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,251 in reported general payments places this provider in the 75th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $199,028 |
| JardianceEmpagliflozin | 173 | $155,085 |
| TrulicityDulaglutide | 68 | $79,922 |
| MounjaroTirzepatide | 47 | $56,704 |
| TradjentaLinagliptin | 51 | $49,892 |
| RybelsusSemaglutide | 19 | $43,152 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $32,985 |
| FarxigaDapagliflozin Propanediol | 35 | $32,489 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $25,007 |
| Testosterone | 147 | $22,902 |
| Humulin R U-500Insulin Regular, Human | 14 | $21,650 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $20,090 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $18,244 |
| XyostedTestosterone Enanthate | 23 | $14,967 |
| Humalog Kwikpen U-100Insulin Lispro | 46 | $14,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $669 | $242,180155 claims |
| Boehringer IngelheimJardiance, Tradjenta | $45 | $204,977224 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $123 | $136,626115 claims |
| AstraZenecaFarxiga | $124 | $32,48935 claims |
| Antares Pharma, Inc.Xyosted | $5,269 | $14,96723 claims |
| AbbVieSynthroid | $293 | $4,58075 claims |
| IBSA Pharma Inc.Tirosint | $17 | $2,44917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Fall River
- Tamer YacoubFall River$1.4M
- David NathanBoston$9M
- Vanita ArodaBoston$4.2M
- George KingBoston$3.7M
- Karen MillerBoston$2.9M
- Steven GrinspoonBoston$2.7M
- Jason GagliaBoston$2.5M
- Elaine YuBoston$1.3M
- Osama HamdyBoston$1.1M
- Steven RussellBoston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.